SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  August 10, 2005

 

United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)

 

 

 

Registrant’s telephone number, including area code:
(301) 608-9292

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01.  Other Events.

 

On August 10, 2005, the Company issued a press release announcing the results of the European Union Mutual Recognition Procedure with respect to marketing authorization approvals for Remodulin®.  A copy of this press release is attached hereto as Exhibit 99.1.

 

Item 9.01.  Exhibits

 

(c)  Exhibits

 

Exhibit No.		Description of Exhibit
99.1		Press release dated August 10, 2005

 

 

2

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		UNITED THERAPEUTICS CORPORATION
Dated: August 10, 2005		By:	/s/ Paul A. Mahon
		Name:		Paul A. Mahon
		Title:		General Counsel

 

 

3

 

EXHIBIT INDEX

 

Exhibit No.		Description of Exhibit
99.1		Press release dated August 10, 2005

 

 

4